Metraipolis › archive › dc_d99fab7bdbe4

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report — Europe PMC PMID:41487577

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41487577
DOI
10.3389/fonc.2025.1723763
License (as archived)
solo-consultazione
Archived
2026-11-07T13:48:06.853Z
SHA-256 of the archived text
9feb8c23ae8cd886e73cde7782740da611216cf34c7e5ea7bd71913c39ae5593
Stable URL of this page
https://metraipolis.com/documento/dc_d99fab7bdbe4

How to cite

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report — Europe PMC PMID:41487577 — Europe PMC (en), https://europepmc.org/article/MED/41487577 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d99fab7bdbe4 (Metraipolis archive dc_d99fab7bdbe4, sha256 9feb8c23ae8cd886e73cde7782740da611216cf34c7e5ea7bd71913c39ae5593)
BibTeX
@misc{dcd99fab7bdbe4,
  title = {Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report — Europe PMC PMID:41487577},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41487577},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d99fab7bdbe4; sha256 9feb8c23ae8cd886e73cde7782740da611216cf34c7e5ea7bd71913c39ae5593},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41487577. Agents can read the archived copy with the MCP tool read_document.